Demethyleneberberine: Mechanisms and Evidence for NF-κB Pathway Inhibition

Executive Summary: Demethyleneberberine (DMB, CAS No. 25459-91-0) is a natural isoquinoline alkaloid derived from traditional Chinese medicines such as Phellodendron bark and is a major metabolite of berberine (Zhao et al. 2022). DMB is a validated inhibitor of the NF-κB and MAPK signaling pathways, with documented anti-inflammatory activity in dextran sulfate sodium (DSS)-induced ulcerative colitis models and in vitro macrophage assays (DOI). The compound also demonstrates neuroprotective, anti-fibrotic, and anti-tumor properties, notably suppressing non-small cell lung cancer (NSCLC) proliferation and metastasis. Mechanistically, DMB blocks TLR4-mitochondria signaling and NLRP3 inflammasome-mediated IL-1β maturation, and activates the AMPK pathway. DMB is available from APExBIO (SKU N2087) at ≥98% purity (product page) and is widely used in well-defined cell culture and animal models.

Biological Rationale

DMB is a natural isoquinoline alkaloid structurally related to berberine. It is isolated from Phellodendron bark and Coptis chinensis rhizome, both used in traditional Chinese medicine (Zhao et al. 2022). DMB’s primary biomedical interest arises from its multi-targeted modulation of inflammation and cell survival pathways. Chronic inflammatory diseases such as ulcerative colitis (UC) and autoimmune hepatitis are characterized by dysregulated immune responses involving NF-κB, MAPK, and TLR4 signaling. DMB’s ability to inhibit these pathways positions it as a tool compound for dissecting innate immune responses and for benchmarking anti-inflammatory strategies (Contrast: This article extends previous mechanism-focused reviews by quantifying DMB’s efficacy in vivo and in vitro.).

Mechanism of Action of Demethyleneberberine

DMB exerts its bioactivity by targeting several intracellular signaling pathways:

• NF-κB inhibition: DMB blocks the phosphorylation and nuclear translocation of NF-κB p65, reducing expression of pro-inflammatory cytokines such as IL-1β and TNF-α (Zhao et al. 2022).
• MAPK pathway suppression: DMB reduces phosphorylation of ERK, JNK, and p38 MAPK, key signaling molecules in inflammation and stress response.
• c-Myc/HIF-1α pathway modulation: DMB downregulates c-Myc and HIF-1α expression, contributing to anti-tumor effects in NSCLC models.
• AMPK activation: DMB increases AMPK phosphorylation, promoting cellular energy balance and anti-inflammatory effects.
• TLR4-mitochondria signaling blockade: DMB prevents excessive mitochondrial biosynthesis and ROS production, thereby attenuating NLRP3 inflammasome activation and maturation of IL-1β.
• MAO-B inhibition: DMB reversibly inhibits monoamine oxidase B, supporting potential neuroprotective applications.

In vitro, DMB is effective at 10–80 μM concentrations in RAW264.7 macrophages and NSCLC cell lines (A549, NCI-H1299), and at 2 mM in HcoEpiC colonic epithelial cells for distribution studies. In vivo dosing ranges from 7.5 to 200 mg/kg/day depending on the model and administration route (Contrast: This article updates scenario-driven dosing guidance with mechanistic endpoints.).

Evidence & Benchmarks

• DMB at 50 mg/kg/day orally for 98 days is non-toxic and significantly reduces colon atrophy, neutrophil infiltration, and histological damage in DSS-induced ulcerative colitis mouse models (Zhao et al. 2022).
• DMB (10–80 μM) in RAW264.7 macrophages suppresses LPS-induced pro-inflammatory cytokine production and NLRP3 inflammasome activation (Table 1, Figure 3).
• DMB inhibits mitochondrial overactivation, maintaining mitochondrial homeostasis during inflammatory challenge (Results, Figure 4).
• In NSCLC xenograft models, DMB reduces tumor volume and metastasis through c-Myc/HIF-1α and MAPK suppression (internal review).
• High-purity DMB from APExBIO (SKU N2087) demonstrates batch reproducibility and solubility at ≥50.1 mg/mL in DMSO, standardizing cell culture workflows (product specification).

Applications, Limits & Misconceptions

Validated Research Applications

• DSS-induced ulcerative colitis models (in vivo): inflammation scoring, colon length/atrophy, neutrophil infiltration.
• RAW264.7 macrophage and primary intestinal macrophage assays (in vitro): cytokine profiling, inflammasome activation, cell viability.
• NSCLC cell lines (A549, NCI-H1299): cell cycle arrest, apoptosis, migration/invasion assays.
• Autoimmune hepatitis and liver fibrosis models: biomarker and histopathology endpoints.
• Neurodegeneration (Huntington’s disease, 3-NPA): MAO-B inhibition and neuroprotection.

Common Pitfalls or Misconceptions

• DMB is not water-soluble and must be dissolved in DMSO (≥50.1 mg/mL) or ethanol (≥2.57 mg/mL) with gentle warming and ultrasonic treatment (APExBIO).
• Exceeding recommended in vitro concentrations (>80 μM) may result in off-target cytotoxicity and confound mechanistic readouts (Contrast: This guide details real-world cell viability limits not addressed here.).
• DMB does not reverse established fibrosis in late-stage liver or colonic models; efficacy is limited to early/intervention stages.
• Not all inflammatory models are responsive: DMB shows minimal effect in TLR4/NLRP3 knockout or IL-1β-deficient systems.
• Long-term DMB solutions are not stable; fresh aliquots should be prepared for each use (APExBIO storage note).

Workflow Integration & Parameters

• In vitro concentrations: 10–80 μM in RAW264.7, A549, NCI-H1299; 2 mM for HcoEpiC distribution studies.
• In vivo dosing: 7.5–200 mg/kg/day, route dependent (oral, intraperitoneal), with 50 mg/kg/day validated as non-toxic for up to 98 days (Zhao et al. 2022).
• Solubility: ≥50.1 mg/mL in DMSO, ≥2.57 mg/mL in ethanol; insoluble in water.
• Storage: -20°C; avoid long-term storage of solutions.
• Vendor reliability: APExBIO (SKU N2087) provides ≥98% purity and batch data (Contrast: This article focuses on protocol integration; here, mechanistic endpoints are emphasized.).

Conclusion & Outlook

Demethyleneberberine is a high-purity, mechanistically validated inhibitor of the NF-κB and MAPK pathways suitable for anti-inflammatory, anti-fibrotic, anti-tumor, and neuroprotective research. Peer-reviewed evidence demonstrates efficacy in ulcerative colitis, autoimmune hepatitis, and NSCLC models with defined dosing and workflow parameters. While DMB’s utility is robust in defined preclinical models, its effectiveness is constrained in genetic knockout or advanced disease settings. For reliable sourcing and reproducibility, APExBIO’s Demethyleneberberine (SKU N2087) is recommended for research applications. For further context on real-world workflows and comparative analysis, see the scenario-driven lab solutions guide (this article extends mechanistic clarity and protocol specifics relative to linked content).